Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
April 08 2021 - 8:30AM
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the
“Company”), a clinical-stage biopharmaceutical company focused on
oncology and rare diseases, today announced that Company management
will present at the 20th Annual Needham Virtual Healthcare
Conference on Monday, April 12, 2021 at 11:00am Eastern Time.
A live audio webcast of the presentation can be
accessed through the Investors section of the company’s website at
www.mereobiopharma.com/investors. An archived replay of the
webcast will be available on the company’s website for two weeks
following the live presentation.
About Mereo BioPharmaMereo
BioPharma is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to
improve outcomes for oncology and rare diseases. The Company has
developed a portfolio of six clinical stage product candidates.
Mereo’s lead oncology product candidate, etigilimab (Anti-TIGIT),
has recently advanced into an open label Phase 1b/2 basket study
evaluating Anti-TIGIT in combination with an anti-PD-1 in a range
of tumor types including three rare tumors and a number of
gynecological carcinomas including cervical, ovarian and
endometrial carcinomas. The Company’s second oncology product,
navicixizumab, for the treatment of late line ovarian cancer, has
completed a Phase 1 study and has been partnered with OncXerna
Therapeutics, Inc., formerly Oncologie, Inc. The Company has two
rare disease product candidates: alvelestat for the treatment of
severe Alpha-1 antitrypsin deficiency (AATD), which is being
investigated in an ongoing Phase 2 proof-of-concept study in the
U.S. and Europe, for which the Company expects to report top line
data in late 2021, and setrusumab for the treatment of osteogenesis
imperfecta (OI). Following the completion of the Company’s Phase 2b
ASTEROID study, the Company met with both the FDA and the European
Medicines Agency (EMA) to discuss the principles of a design of a
single Phase 2/3 registrational pediatric study in OI. In September
2020, the FDA granted Rare Pediatric Disease designation to
setrusumab for the treatment of OI. In December 2020, the Company
signed a license and collaboration agreement for setrusumab in OI
with Ultragenyx Pharmaceutical Inc.
Forward-Looking StatementsThis
press release contains “forward-looking statements.” All statements
other than statements of historical fact contained in this press
release are forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the United States
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Forward-looking statements usually relate to future events and
anticipated revenues, earnings, cash flows or other aspects of our
operations or operating results. Forward-looking statements are
often identified by the words “believe,” “expect,” “anticipate,”
“plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,”
“estimate,” “outlook” and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company’s current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company’s forward-looking statements
involve known and unknown risks and uncertainties some of which are
significant or beyond its control and involve assumptions that
could cause actual results to differ materially from the Company’s
historical experience and its present expectations or projections.
You should carefully consider the foregoing factors and the other
risks and uncertainties that affect the Company’s business,
including those described in the “Risk Factors” section of its
latest Annual Report on Form 20-F, reports on Form 6-K and other
documents furnished or filed from time to time by the Company with
the SEC. The Company wishes to caution you not to place undue
reliance on any forward-looking statements, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update or revise any forward-looking statements after the date they
are made, whether as a result of new information, future events or
otherwise, except to the extent required by law.
Mereo BioPharma Contacts: |
|
|
|
Mereo |
+44 (0)333 023 7300 |
|
|
Denise Scots-Knight, Chief Executive Officer |
|
|
|
Christine Fox, Chief Financial Officer |
|
|
|
Burns McClellan (Investor Relations Adviser to
Mereo) |
+01 212 213 0006 |
|
|
Lee Roth |
|
|
|
Investors |
investors@mereobiopharma.com |
Medicure (TSXV:MPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicure (TSXV:MPH)
Historical Stock Chart
From Sep 2023 to Sep 2024